Table 3.
Factors associated with the primary renal outcome by COX regression analysis
| Variables | Crude HR | Adjusted HRa | ||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Visfatin: per 1ng/ml | 1.09 (1.05–1.13) | <0.001 | 1.09 (1.05–1.13) | <0.001 |
| Fasting blood glucose: per 1mg/dl | 1.01 (1.00–1.02) | 0.002 | 1.01 (1.00–1.02) | 0.020 |
| Flow-mediated dilatation: per 1% change | 0.85 (0.75–0.96) | 0.010 | 0.87 (0.76–1.00) | 0.049 |
| Systolic blood pressure: per 1mm Hg | 1.05 (1.01–1.10) | 0.019 | 1.02 (0.97–1.07) | 0.453 |
| RAS blockerb use: user vs. nonuser | 0.52 (0.28–0.94) | 0.031 | 0.73 (0.37–1.44) | 0.358 |
| Age: per 1 year | 1.03 (1.00–1.06) | 0.056 | 1.02 (0.98–1.05) | 0.339 |
| Statin use: user vs. nonuser | 0.52 (0.23–1.17) | 0.114 | ||
| Calcium channel blocker use: user vs. nonuser | 0.63 (0.34–1.19) | 0.157 | ||
| hsCRP level: per 1mg/l | 1.08 (0.96–1.21) | 0.193 | ||
| Body mass index: per 1kg/m2 | 0.99 (0.96–1.02) | 0.379 | ||
| Framingham risk score: per 1% | 1.00 (0.99–1.01) | 0.531 | ||
| Uric acid level: per 1mg/dl | 1.05 (0.86–1.27) | 0.634 | ||
| LDL-cholesterol level: per 1mg/dl | 1.00 (0.99–1.01) | 0.743 | ||
| Baseline GFR: per 1ml/min/1.73 m2 | 1.00 (0.99–1.01) | 0.920 | ||
| Triglyceride level: per 1mg/dl | 1.00 (1.00–1.00) | 0.961 | ||
Abbreviations: CI, confidence interval; HR, hazard ratio; GFR, glomerular filtration rate; LDL, low-density lipoprotein-cholesterol; hsCRP, high-sensitivity C-reactive protein; RAS, renin-angiotensin system.
aThe adjusted COX regression model included all available variables with crude HR P value < 0.100. bRAS blocker, renin-angiotensin system blocker, including angiotensin converting enzymes (ACE) inhibitors, angiotensin receptor blockers (ARB), and direct renin inhibitors (DRI).